What is your approach for choosing between Imetelstat and Luspatercept in managing MDS related anemia?

In the past 18 months, between the COMMANDS trial looking at Luspatercept in expanded indications beyond just patients with MDS-RS and the IMerge trial looking at the use of Imetelstat in patients with low-risk MDS, we now have many more options for these patients.

The COMMANDS trial looked at Luspat...